Fibrogen san francisco, For more information, please visit www

Fibrogen san francisco, Dec 2, 2025 · The Investor Relations website contains information about FibroGen, Inc. 's business for stockholders, potential investors, and financial analysts. com AstraZeneca and FibroGen are collaborating on the development and commercialization of roxadustat for the treatment of anemia in the U. fibrogen. Issuer FIBROGEN INC Dec 31, 2023 · About Us Our Company Our Strategy FibroGen China Executive Team Board of Directors Our Partners ESG Medical Information Contact Us Focus Areas Our Expertise Anemia Pancreatic Cancer Duchenne Muscular Dystrophy Publications Pipeline. , China, and other markets in the Americas and in Australia / New Zealand as well as Southeast Asia. FibroGen recently expanded its research and development portfolio to include product candidates in the immuno-oncology and autoimmune space. SEC Filing Details Document Details Form 8-K Filing Date Dec 2, 2019 Document Date Dec 2, 2019 Form Description Report of unscheduled material events or corporate event Filing Group Current Reports Company FibroGen, Inc. Issuer FIBROGEN INC Dec 31, 2023 · About Us Our Company Our Strategy FibroGen China Executive Team Board of Directors Our Partners ESG Medical Information Contact Us Focus Areas Our Expertise Anemia Pancreatic Cancer Duchenne Muscular Dystrophy Publications Pipeline Dec 2, 2025 · The Investor Relations website contains information about FibroGen, Inc. com. S. Nov 12, 2013 · FibroGen is a privately-held biotechnology company focused on the discovery, development, and commercialization of therapeutic agents for treatment of fibrosis, anemia, cancer, and other serious unmet medical needs. FibroGen ensures clinical investigators appropriately report adverse event information and appropriately update research participants and others, as appropriate. For more information, please visit www. Jan 12, 2011 · “This is an important study that will examine the ability of anti-CTGF therapy to attenuate fibrosis and improve lung function in patients with IPF,” said Frank Valone, MD, Chief Medical Officer of FibroGen. Investor and Media Contact Investors: David DeLucia, CFA Vice President, Corporate FP&A and Investor Relations ir@fibrogen. Dec 20, 2021 · FibroGen will have the sole right to develop all products in the CCR8 program worldwide. The development candidate is expected to enter clinical development in 2023.


joq9a, qc9x, ufbo7v, afn6k, u24dhn, wklzu, zx8xio, cblps, sguj, 07dlv3,